Sidan kan innehålla länkar till samarbetspartners, läs mer i vår Dataskyddspolicy.

Xvivo Perfusion

Xvivo Perfusion är verksamma inom medicinteknik. Bolaget tillhandahåller lösningar för transplantation av lungor. Exempel på produkter som bolaget levererar innefattar kanyler, organförvaring samt kyllösningar. Produkterna vidaresäljs till kliniker och forskningsinstitut på global nivå. Bolaget kom till via en avknoppning från Vitrolife under 2012 och har sitt huvudkontor i Göteborg.

Börsvärde

4,788 MSEK

Omsättning

220 MSEK

Vinst

-6 MSEK

P/E

-742.6

P/S

24.7

Nyheter
Blogginlägg
Videos
Insynshandel
Finwire / Börskollen •  24 Jul 10:31

Calmark utser ny produktions- och logistikchef

Calmark har anställt Jim Hansson i rollen som produktions- och logistikchef, med tillträde i oktober.

Redeye •  10 Jul 14:37

Xvivo Perfusion Q2: Short-term impact bigger than expected

Sales in Q2 came in considerably lower than expected, we underestimated the impact that the Covid-19 had primarily on ICU’s.

Redeye •  10 Jul 06:56

Xvivo Perfusion Q2: First impression

Redeyes first impression on the Q2 results.

Redeye •  09 Jul 08:30

Xvivo Perfusion: Q2 preview

Redeye: Xvivo is scheduled to release its second-quarter earnings results tomorrow before the stock market opens.

Redeye •  15 Jun 06:20

Xvivo: Positive results from study

Redeye sees the results from a study published about heart transplants as another positive sign.

Redeye •  29 May 12:58

Xvivo Perfusion: Well-preserved value

Redeye re-initiates coverage of Xvivo with strengthened conviction following a deep dive into its clinical data and that of key competitor TransMedics, as well as target markets.

Redeye •  19 May 07:04

Xvivo Perfusion: XPS to leading European clinic

Xvivo has sold an XPS to the AKH University Hospital in Vienna, Austria.

Du har väl inte missat våra bolagssidor?

Här hittar du allt om ett enskilt bolag. Utöver nyheter, videos, blogginlägg och insynshandel så hittar du även nyckeltal och bra relaterade länkar till bolagens hemsida men även direktlänkar till verktyg för analys m.m.

Redeye •  29 Apr 06:36

Xvivo Perfusion: Announces CEO transition

Xvivo announces that Magnus Nilsson will step down and that Dag Andersson is appointed as the new CEO.

Börsvärlden •  27 Apr 04:50

Börsveckan ger köpråd för Byggmax, Getinge, GHP, Rejlers och Nyfosa

Börsveckan rekommenderar köp av Byggmax, Getinge, GHP, Rejlers och Nyfosa i den senaste utgåvan.

Börsvärlden •  14 Apr 11:00

Xvivo-rapport bättre än väntat enligt Pareto som höjer riktkursen

Pareto Securities höjer riktkursen för medicinteknikbolaget Xvivo Perfusion till 110 kronor (83) efter att Q1-rapporten visat sig vara bättre än väntat.

Privata Affärer •  09 Apr 06:40

Börsuppgången mattades av

Vid stängning klockan 13.00 var Stockholmsbörsens OMXS30-index ner 0,1 procent till nivån 1.

Redeye •  09 Apr 06:38

Xvivo Perfusion Q1: Better than expected

Sales in Q1 came in higher than expected and EBITDA beat our forecast by a margin.

Redeye •  08 Apr 10:22

Xvivo Perfusion: Q1 preview

Xvivo is scheduled to release its first-quarter earnings results tomorrow before the stock market opens.

Redeye •  31 Mar 08:02

Xvivo Perfusion: First XPS to pediatric hospital

Xvivo reports that the company has sold the first XPS to a pediatric hospital.

Redeye •  18 Mar 08:10

Xvivo Perfusion: Guidance on coronavirus impact

Xvivo reports a decline in demand for transplant products due to the Covid-19 epidemic and expects the negative impact to continue through at least the next quarter.

Börsvärlden •  31 Jan 10:13

Xvivos rapport var bra men inte tillräckligt för en rekommendationsändring – Pareto

Xvivo Perfusion avslutade fjolåret med flera uppfyllda milstolpar men ebitda kom in 37 procent under förväntan på högre försäljningskostnader än väntat, skriver Pareto Securities i en marknadskommentar.

Redeye •  30 Jan 09:07

Xvivo Perfusion Q4: Fails to beat our forecast

Sales in Q4 came in lower than expected, but the EBITDA was in line with our estimate.

Redeye •  29 Jan 07:51

Xvivo Perfusion: Q4 preview

Xvivo is scheduled to release its fourth-quarter earnings results tomorrow before the stock market opens.

Redeye •  18 Dec 2019 06:53

Xvivo Perfusion: CFO Christoffer Rosenblad comments on BDD

Xvivo was recently granted Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for the Xvivo Heart Preservation System (XHPS).

Redeye •  16 Dec 2019 10:48

Xvivo Perfusion: Breakthrough device designation for XHPS

Xvivo reports that the company has been granted breakthrough device designation (BDD) from the US FDA for the XVIVO Heart Preservation System (XHPS).

Redeye •  30 Oct 2019 07:37

Xvivo Perfusion: Third XPS to Australia

Xvivo reports that they have sold an XPS to Fiona Stanley Hospital in Perth, Australia.

Redeye •  25 Oct 2019 06:25

Xvivo Perfusion: Moving the needle

Sales came in higher than we expected in Q3 and also beat the street expectation.

Redeye •  24 Oct 2019 07:21

Xvivo Perfusion Q3: Beats our expectations

Sales in Q3 came in higher than expected. Revenues related to warm perfusion (excluding durable goods) came in close to our estimate, but sales related to cold preservation and durable goods exceeded our expectations significantly.

Redeye •  23 Oct 2019 14:43

Xvivo Perfusion: New subsidiary in Australia

Xvivo announces that the company plans to open a subsidiary in Australia.

IPO.se •  23 Oct 2019 10:00

XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019/2021 fulltecknat

Årsstämman i XVIXO Perfusion AB (publ) (”XVIVO”) beslutade den 25 april 2019 att emittera högst 351 000 teckningsoptioner av serie 2019/2021 till anställda i XVIVO och XVIVO:s svenska dotterbolag med anställningsdatum senast den 18 oktober 2019.

Redeye •  23 Oct 2019 03:50

Xvivo Perfusion: Q3 expectations

Xvivo is scheduled to release the results for the quarter ended September 30, 2019, tomorrow before the stock market opens.

Redeye •  18 Sep 2019 07:04

Xvivo Perfusion: Second XPS to China

Xvivo shared positive news today, reporting that they have sold an XPS to China’s second largest lung transplant clinic.

Redeye •  23 Aug 2019 06:36

Xvivo Perfusion: Lung Bioengineering to use XPS in new center

Xvivo announced that Lung Bioengineering has chosen to purchase another XPS to use in its new ex vivo lung perfusion (EVLP) center in Jacksonville, Florida.

Redeye •  21 Aug 2019 09:42

Xvivo Perfusion: Receives patent for Perfadex Plus

Xvivo Perfusion announces that the company has received a patent approval for Perfadex Plus, a second-generation of the lung preservation solution Perfadex.

Redeye •  17 Jul 2019 09:03

Xvivo Perfusion: Collaboration to develop diagnostic tool

Xvivo announces that the company will collaborate with MyCartis to develop a fast diagnostic test that can assess the quality of a donated organ before transplantation.

Redeye •  12 Jul 2019 09:19

Xvivo Perfusion: Keeps trucking forward

Sales in Q2 were in line with expectations. Sales related to warm perfusion (excluding durable goods) did not live up to expectations, but we see that the steadily expanding installed base indicates that strong growth opportunities lie ahead.

Redeye •  11 Jul 2019 13:04

Xvivo Perfusion: Q2 Expectations

Xvivo is scheduled to release the results for the quarter ended June 30, 2019, tomorrow before the stock market opens.

Redeye •  15 May 2019 14:29

Xvivo Perfusion: Go-ahead for Heart Trial

Xvivo announded that the company has received approval from the Swedish Medical Products Agency (MPA) to initiate the heart transplant trial.

Börsvärlden •  03 May 2019 07:52

Xvivo Perfusions konkurrent upp 40 procent i börsdebuten

Medicinteknikbolaget Xvivo Perfusions närmaste konkurrent Transmedics Group ökade nära 40 procent vid börsdebuten i USA.

Redeye •  03 May 2019 07:17

Xvivo Perfusion: First XPS to Canadian Clinic

Xvivo announces that the first XPS has been sold to a Canadian clinic.

Redeye •  02 May 2019 08:51

Xvivo Perfusion: Heart Preservation Fluid Approved in the US and Europe

Xvivo announces that the company’s patent for the heart preservation fluid has been approved in the US and Europe.

Redeye •  02 May 2019 08:51

Xvivo Perfusion: Patent for Heart Preservation Fluid Approved

Xvivo announces that the company’s patent for the heart preservation fluid has been approved in the US and Europe.

Redeye •  29 Apr 2019 08:14

Xvivo Perfusion: PMA in hand

Xvivo Perfusion (Xvivo) announced late Friday that the company has received premarket approval (PMA) for the XPS and STEEN Solution.

Aktiespararna •  29 Apr 2019 05:07

Xvivo får FDA-godkännande

Medicinteknikbolaget Xvivo har fått ett så kallat PMA-godkännande från den amerikanska hälsovårdsmyndigheten FDA avseende produkterna XPS och Steen Solution för försäljning på den amerikanska marknaden.

Redeye •  24 Apr 2019 07:38

Xvivo Perfusion: A mixed bag

Sales failed to live up to our high set expectations in the first quarter of the year.

Affärsvärlden •  24 Apr 2019 05:39

Röda siffror för Xvivo

Bioteknikföretaget rapporterar en förlust för kvartalet.

Redeye •  23 Apr 2019 05:50

Xvivo Perfusion: Q1 Expectations

Xvivo is scheduled to release the results for the quarter ended March 31, 2019, on Wednesday, April 24, 2019, before the stock market opens.

SVD Näringsliv •  13 Feb 2019 10:16

Avsnitt 42: Life Science

Specialavsnitt om medicinteknik och ett par läkemedelsbolag.

SVD Näringsliv •  08 Feb 2019 14:11

Alla Börsplus analyser vecka 6

Analyser av: Orexo, Ortoma, Husqvarna, BE Group, Gunnebo, Nordea, Biogaia, Hexpol, Catena Media, Xvivo Perfusion samt portföljgenomgång och råduppföljning.

Redeye •  08 Feb 2019 08:00

Xvivo Perfusion Q4: Strong end to 2018

Sales in Q4 came in higher than expected and sales related to warm perfusion showed continued strong growth.

Redeye •  02 Nov 2018 06:30

Xvivo Perfusion: Strong Growth Ahead

Xvivo Perfusion delivered a strong quarter for sales related to warm perfusion (excluding durable goods).

Redeye •  26 Oct 2018 07:40

Xvivo Perfusion Q3: Continued strong growth for warm perfusion

Sales in Q3 came in lower than expected, but sales related to warm perfusion were in line with our forecast and saw continued strong growth.

Redeye •  16 Aug 2018 05:30

Xvivo Perfusion: Harvest Season is Coming

We have conducted a survey to transplant physicians in the United States and Europe.

Redeye •  20 Jul 2018 07:47

Xvivo Perfusion: Strong growth in Q2

Sales in Q2 were in line with our forecast and showed strong growth of sales related to warm perfusion.

Redeye •  25 Jun 2018 08:15

Xvivo Perfusion: Perfadex Plus gets FDA nod

Xvivo Perfusion reported during the morning that Perfadex Plus has received a 510(k) market approval.

Redeye •  12 Jun 2018 06:53

Xvivo Perfusion: Collaboration with United Therapeutics

Xvivo Perfusion announced a collaboration with United Therapeutics during the morning, where the two companies will work to reduce organ shortage.

Redeye •  06 Jun 2018 04:20

Xvivo Perfusion: Perfedex Plus launched

Xvivo announced that the company now has launched Perfadex Plus, a second-generation of their product used to preserve lungs before transplantation.

Redeye •  06 Jun 2018 04:20

Xvivo Perfusion: Perfadex Plus launched

Xvivo announced that the company now has launched Perfadex Plus, a second-generation of their product used to preserve lungs before transplantation.

Redeye •  14 May 2018 15:44

Xvivo Perfusion: Positive results from the PrimECC study

The analysis of the clinical trial with PrimECC showed positive findings.

Redeye •  11 May 2018 09:19

Xvivo Perfusion: PMA application submitted

Xvivo Perfusion announced this morning that the premarket approval (PMA) application for Steen Solution and the XPS has been submitted to the FDA.

Redeye •  09 May 2018 05:50

Xvivo Perfusion: High Activity Ahead

Sales of consumables in Q1 were in line with our forecast, but total sales beat our estimates due to higher-than-expected sales of durable goods.

Redeye •  26 Apr 2018 07:28

Xvivo Perfusion Q1: High profitability, high activity

Sales in Q1 came in slightly higher than our forecast due to higher-than-expected sales of durable goods.

Redeye •  28 Mar 2018 07:45

Xvivo Perfusion: Approaching Next Phase

With CPT codes in hand, covering the whole EVLP procedure and simplifying the process of obtaining reimbursements for hospitals performing EVLP, our conviction of a strong year for STEEN Solution in 2018 is strengthened.

Redeye •  09 Feb 2018 09:30

Xvivo Perfusion Q4: Strong profitability

Sales in Q4 came in slightly higher than our forecast.

Börsvärlden •  14 Dec 2017 11:23

Dagens aktierekommendationer i översikt – Köprek för bemanningsföretag inom vården

I tabellen nedan visas ett axplock av de rekommendationsnyheter som Finwire News har rapporterat om i dag.

Redeye •  01 Dec 2017 08:58

Xvivo Perfusion: First XPS in China

Xvivo Perfusion announced during the morning that an XPS has been installed at the Shanghai Pulmonary Hostpital.

Redeye •  15 Nov 2017 06:30

Xvivo Perfusion: Please hold

• Xvivo Perfusion failed to live up to our high set expectations in Q3, causing us to revise our estimates with lower sales growth in the near-term.

Redeye •  07 Nov 2017 08:05

Xvivo Perfusion: Reimbursement codes for EVLP procedure

Xvivo Perfusion announced during the morning that the company has obtained CPT (current procedural terminology) codes for the EVLP (ex vivo lung perfusion) process.

Redeye •  27 Oct 2017 08:00

Xvivo Perfusion Q3: Below expectations

Sales in Q3 came in lower than our forecast, affected by a negative currency effect.

Redeye •  12 Sep 2017 13:10

Xvivo Perfusion: First clinical heart transplant performed

Xvivo Perfusion has announced that the first clinical heart transplant has been performed using the company's technology for warm perfusion.

Redeye •  28 Jul 2017 07:05

Xvivo Perfusion: Margin expansion ahead

• Sales in Q2 came in below our expectations, with lower than expected sales of XPS and STEEN Solution.

Redeye •  17 Jul 2017 05:06

Xvivo Perfusion Q2: Return to profitability

Net sales in Q2 came in slightly lower than our forecast.

Redeye •  13 Jul 2017 10:53

Xvivo Perfusion: Recruitment of the PrimECC study is completed

Xvivo Perfusion announced during the morning that the PrimECC study now is fully recruited.

Redeye •  06 Jul 2017 12:57

Xvivo Perfusion: NOVEL study is fully recruited

With a total of 220 (110+110) patients included, the recruitment of the NOVEL study has now been completed.

Redeye •  19 May 2017 10:47

Redeye Today: Xvivo Perfusion: FDA panel recommends approval for TransMedic's OCS lung system

An FDA advisory panel has recommended market approval for TransMedic’s device used to perfuse lungs prior to transplantation.

Biostock •  16 May 2017 09:41

Nyhetssvepet tisdag 16 maj

Ett redaktionellt urval av dagens Life Science-nyheter Imorgon utses 2017 års vinnare i SwedenBIO Award, branschens eget pris som årligen och nu för elfte gången tilldelas ett framstående företag i life science-industrin.

Redeye •  10 May 2017 07:24

Redeye Update: Xvivo Perfusion: Patience is a virtue

• Sales in Q1 fell short of our high expectations, but compared to last year sales related to warm perfusion (excl.

Redeye •  25 Apr 2017 09:13

Redeye Today: Xvivo Perfusion Q1: falls short of high expectations

Total sales in Q1 failed to meet our expectations, but sales related to warm perfusion (excl.

Realtid •  19 Apr 2017 07:14

Bures innehav i Xvivo Perfusion minskar

Efter en riktad nyemission i portföljbolaget Xvivo Perfusion minskar Bures innehav i bolaget.

Redeye •  19 Apr 2017 05:49

Redeye Update: Xvivo Perfusion: Pipeline lifts fair value

• Sales in Q4 came in lower than expected. The discrepancy could mainly be attributed to the sales of durable goods.

Redeye •  17 Mar 2017 08:12

Redeye Today: Xvivo Perfusion: riktad emission för att öka takten i kliniska utvecklingsprojekt

Xvivo Perfusion meddelade under torsdagskvällen att bolaget avser att genomföra en riktad emission till institutionella investerare.

Redeye •  08 Feb 2017 11:51

Redeye Today: Xvivo Perfusion: Godkänt Q4 med positiva signaler

Försäljningen i Q4 kom in lägre än vår prognos, men lönsamheten överträffade våra förväntningar och resultatet blev därmed i linje med våra estimat.

Redeye •  13 Jan 2017 07:40

Redeye Update: Xvivo Perfusion: Den som väntar på något gott

Försäljningen i Q3 kom in under våra förväntningar.

Biostock •  28 Nov 2016 10:29

Morgonens nyhetssvep: måndag 28 november 2016

Ett redaktionellt urval från morgonens nyheter inom svensk Life Science.

Affärsvärlden •  21 Nov 2016 16:28

Flyttdatum klart för börsnykomlingen Xvivo

Xvivo Perfusion har fått ett godkännande för att upptas för handel på Nasdaq Stockholm.

Redeye •  27 Oct 2016 14:51

Redeye Today: Xvivo Perfusion: Något svagare Q3 än väntat

Försäljningen i Q3 kom in lägre än våra prognoser, men kostnaderna var också något lägre och resultatet blev därmed något högre än vad vi hade förväntat oss.

SVD Näringsliv •  08 Sep 2016 13:10

Teknisk analys: Köpläge i Rezidor – sälj Lucara

Denna vecka har analysföretaget Investtech analyserat två aktier där den tekniska bilden indikerar positiv utveckling och en aktie som kan komma att vända en positiv trend.

Redeye •  26 Jul 2016 08:13

Redeye Update: Xvivo Perfusion: Breddad portfölj lyfter aktien

Xvivos Q2-rapport var relativt odramatisk, men det verkligen intressanta just nu är förvärvet av Vivoline som håller på att fullföljas.

Redeye •  15 Jul 2016 06:56

Redeye Today: Xvivo Perfusion: Godkänt Q2 med blickar på Vivoline-förvärvet

Försäljningen i Q2 var något lägre än vi räknat med, men resultatet slog vår prognos om man justerar för engångskostnader.

Redeye •  22 Jun 2016 08:08

Redeye Today: Xvivo Perfusion: Första cancerbehandlingen utförd

Bolaget har tidigare talat om potentialen för in vivo lung perfusion där lokal cancerbehandling av lunga utförs genom att cirkulera Steen Solution tillsammans med ett läkemedel.

Redeye •  10 Jun 2016 13:09

Redeye Update: Xvivo Perfusion: Bid on Vivoline in focus

Note: This is a translation of the original report, written in Swedish, released on June 7th.

Redeye •  08 Jun 2016 07:33

Redeye Today: Xvivo Perfusion: Budet går igenom

Mer än 90 procent accepterade Xvivos bud på Vivoline och därmed kommer förvärvet fullföljas.

Biostock •  08 Jun 2016 06:30

Xvivos uppköpsbud på Vivoline accepterat till över 90 procent

Det offentliga bud på Vivoline Medical AB som lades fram av XVIVO Perfusion den 18 april har accepterats till 94,5 procent av Vivolines aktieägare.

Biostock •  07 Jun 2016 14:20

Deadline närmar sig för uppköpsbud på Vivoline

Den 18 april i år lämnade XVIVO Perfusion ett offentligt uppköpsbud på Vivoline Medical och idag tisdag 7 juni kl 17 löper acceptperioden för erbjudandet ut för Vivolines aktieägare.

Redeye •  07 Jun 2016 07:39

Redeye Update: Xvivo Perfusion: Budet på Vivoline i fokus

Den 18 april lade Xvivo Perfusion ett bud på Vivoline.

Vi har inte hittat några nyheter än.